This is a single-arm feasibility trial in which patients with histologically confirmed plasmablastic lymphoma (PBL) with or without HIV, who have achieved a Complete Response or Partial Response after definitive frontline chemotherapy, will receive Elranatamab (Elra) consolidation.
Age ≥ 18 years at time of consent
ECOG performance status (PS) 0 or 1
Histologically and immunophenotypically confirmed PBL
Ann Arbor stage at initial diagnosis: stage I with lactate dehydrogenase (LDH) > upper limit of normal (ULN) and/or bulky disease >7.5 cm or stage II-IV
Age ≥ 18 years at time of consent
ECOG performance status (PS) 0 or 1
Histologically and immunophenotypically confirmed PBL
Ann Arbor stage at initial diagnosis: stage I with lactate dehydrogenase (LDH) > upper limit of normal (ULN) and/or bulky disease >7.5 cm or stage II-IV
University of Illinois at Chicago
Lead sponsor
Pfizer
Collaborator